Sinovac Biotech Ltd (SVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has a cash flow conversion efficiency ratio of 0.012x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($146.01 Million) by net assets ($12.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sinovac Biotech Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Sinovac Biotech Ltd - Cash Flow Conversion Efficiency Trend (2000–2023)
This chart illustrates how Sinovac Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sinovac Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinovac Biotech Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuhan Sanzhen Industry Holding Co Ltd
SHG:600168
|
0.023x |
|
PPC Ltd
JSE:PPC
|
0.136x |
|
Wagners Holding Company Ltd
AU:WGN
|
0.157x |
|
Ways Electron Co Ltd
SHG:605218
|
0.005x |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
0.028x |
|
Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ:DMII
|
0.000x |
|
Rogers Sugar Inc.
TO:RSI
|
0.099x |
|
Shanghai Baosight Software Co Ltd B
SHG:900926
|
0.054x |
Annual Cash Flow Conversion Efficiency for Sinovac Biotech Ltd (2000–2023)
The table below shows the annual cash flow conversion efficiency of Sinovac Biotech Ltd from 2000 to 2023. For the full company profile with market capitalisation and key ratios, see SVA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $12.02 Billion | $106.02 Million | 0.009x | +114.54% |
| 2022-12-31 | $12.71 Billion | $-770.75 Million | -0.061x | -105.48% |
| 2021-12-31 | $13.88 Billion | $15.35 Billion | 1.106x | +158.56% |
| 2020-12-31 | $1.12 Billion | $479.31 Million | 0.428x | +285.70% |
| 2019-12-31 | $352.19 Million | $39.07 Million | 0.111x | +307.75% |
| 2018-12-31 | $291.93 Million | $7.94 Million | 0.027x | -94.10% |
| 2017-12-31 | $129.67 Million | $59.76 Million | 0.461x | +486.55% |
| 2016-12-31 | $129.67 Million | $-15.46 Million | -0.119x | -486.47% |
| 2015-12-31 | $136.50 Million | $4.21 Million | 0.031x | +143.17% |
| 2014-12-31 | $141.73 Million | $-10.13 Million | -0.071x | -284.07% |
| 2013-12-31 | $143.64 Million | $5.58 Million | 0.039x | +130.91% |
| 2012-12-31 | $129.44 Million | $-16.25 Million | -0.126x | -230.93% |
| 2011-12-31 | $145.30 Million | $13.94 Million | 0.096x | +199.25% |
| 2010-12-31 | $147.76 Million | $-14.28 Million | -0.097x | -116.86% |
| 2009-12-31 | $84.47 Million | $48.41 Million | 0.573x | +192.64% |
| 2008-12-31 | $53.64 Million | $10.50 Million | 0.196x | +49.30% |
| 2007-12-31 | $32.90 Million | $4.32 Million | 0.131x | +270.93% |
| 2006-12-31 | $21.31 Million | $-1.64 Million | -0.077x | -12.10% |
| 2005-12-31 | $16.51 Million | $-1.13 Million | -0.068x | +30.71% |
| 2004-12-31 | $15.56 Million | $-1.54 Million | -0.099x | +37.57% |
| 2003-12-31 | $10.89 Million | $-1.72 Million | -0.158x | +72.89% |
| 2002-12-31 | $99.44K | $-58.05K | -0.584x | -180.57% |
| 2001-12-31 | $-682.96K | $-494.80K | 0.724x | 0.00% |
| 2000-12-31 | $-682.96K | $-494.80K | 0.724x | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more